Hepatoblastoma Overview

Save information for later
Sign Up

Learn About Hepatoblastoma

What is the definition of Hepatoblastoma?
Hepatoblastoma is a rare malignant (cancerous) tumor of the live, usually affecting young children. In early stages of the condition, there may be no concerning signs or symptoms. As the tumor gets larger, affected children may experience a painful, abdominal lump; swelling of the abdomen; unexplained weight loss; loss of appetite; and/or nausea and vomiting. The exact underlying cause of Hepatoblastoma is poorly understood. Risk factors for the tumor include prematurity with a very low birth weight, early exposure to hepatitis B infection, biliary atresia, and several different genetic conditions (i.e. Beckwith-Wiedemann syndrome, familial adenomatous polyposis, Aicardi syndrome, Glycogen storage disease, and Simpson-Golabi-Behmel syndrome).
What are the alternative names for Hepatoblastoma?
  • Hepatoblastoma
Who are the top Hepatoblastoma Local Doctors?
Rakesh K. Sindhi
Elite in Hepatoblastoma
Dr. Rakesh K. Sindhi
General Surgery
Elite in Hepatoblastoma
Dr. Rakesh K. Sindhi
General Surgery

Atrium Health Transplant Center, A Facility Of Carolinas Medical Center

1025 Morehead Medical Drive, Suite 600, 
Charlotte, NC 
704-355-6649
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rakesh Sindhi is a General Surgeon in Charlotte, North Carolina. Dr. Sindhi is rated as an Elite provider by MediFind in the treatment of Hepatoblastoma. His top areas of expertise are Hepatoblastoma, Biliary Atresia, Liver Failure, Liver Transplant, and Small Bowel Resection. Dr. Sindhi is currently accepting new patients.

Elite in Hepatoblastoma
Eiso Hiyama
Elite in Hepatoblastoma
Eiso Hiyama
Hiroshima, JP 

Eiso Hiyama practices in Hiroshima, Japan. Hiyama is rated as an Elite expert by MediFind in the treatment of Hepatoblastoma. Their top areas of expertise are Hepatoblastoma, Neuroblastoma, Liver Cancer, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Hepatoblastoma
Stefano Cairo
Elite in Hepatoblastoma
Stefano Cairo
Evry, FR 

Stefano Cairo practices in Evry, France. Mr. Cairo is rated as an Elite expert by MediFind in the treatment of Hepatoblastoma. His top areas of expertise are Hepatoblastoma, Liver Cancer, Breast Cancer, and Triple-Negative Breast Cancer.

View All Doctors
What are the latest Hepatoblastoma Clinical Trials?
LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
Enrollment Status: Recruiting
Publish Date: December 15, 2025
Intervention Type: Biological
Study Phase: Phase 1/Phase 2

Summary: Researchers are looking for new ways to treat children with hepatoblastoma or rhabdomyosarcoma (RMS) that has relapsed or is refractory: * Hepatoblastoma is a common liver cancer in babies and very young children * RMS is a cancer that starts in muscle cells, often in a child's head and neck, bladder, arms, or legs * Relapsed means the cancer came back after treatment * Refractory means the cancer...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma
A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma
Who is this study for: Children with recurrent solid malignancies and Ewing sarcoma
Enrollment Status: Recruiting
Publish Date: December 02, 2025
Intervention Type: Drug
Study Drugs: Onivyde, Talazoparib, Temozolomide
Study Phase: Phase 1/Phase 2

Summary: The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will test 2 combinations of therapy and participants will be randomly assigned to either Arm A or Arm B. The purpose of the phase I study is to determine the highest ...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center